HOP/OB1/NECC1 promoter DNA is frequently hypermethylated and involved in tumorigenic ability in esophageal squamous cell carcinoma

Molecular Cancer Research

Volumn 6, Issue 1, 2008, Pages 31-41

  Yamashita, Keishi ^a   Kim, Myoung Sook ^a   Park, Hannah Lui ^a   Tokumaru, Yutaka ^a   Osada, Motonobu ^a   Inoue, Hiroshi ^b   Mori, Masaki ^b   Sidransky, David ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; TRICHOSTATIN A;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE FUNCTION; GENE SILENCING; HOPALPHA GENE; HOPBETA GENE; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NECC1 GENE; NUCLEOTIDE SEQUENCE; OB1 GENE; OPEN READING FRAME; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HOMEODOMAIN PROTEINS; HUMANS; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROMOTER REGIONS (GENETICS); PROTEIN ISOFORMS; REPRODUCIBILITY OF RESULTS; RNA INTERFERENCE; RNA, MESSENGER; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEINS;

EID: 40749087229     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-07-0213     Document Type: Article

References (34)

1. Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of gene silenced in cancer. Nat Genet 1999;21:103-7.
2. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
3. Kim MS, Kwon HJ, Lee YM, et al. Histone deacetylase induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001;7:437-43.
4. Belinsky SA, Klinge DM, Stidley CA, et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 2003;63:7089-93.
5. Yamashita K, Upadhyay S, Osada M, et al. Pharmacological unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002;2:485-95.
6. Tokumaru Y, Yamashita K, Osada M, et al. Inverse Correlation between Cyclin A1 Hypermethylation and p53 Mutation in Head and Neck Cancer Identified by Reversal of Epigenetic Silencing. Cancer Res 2004;64:5982-7.
7. Mandelker D, Yamashita K, Tokumaru Y, et al. PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res 2005;65:4963-8.
8. Kim MS, Yamashita K, Baek JH, et al. NMDA receptor type 2B is epigenetically inactivated and exhibits tumor suppressor activity in human esophageal cancer. Cancer Res 2006;66:3409-18.
9. Yamashita K, Upadhay S, Mimori K, et al. Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression. Cancer 2003;97:2412-9.
10. Yamashita K, Tanaka Y, Mimori K, et al. Differential expression of MMP and uPA systems and prognostic relevance of their expression in esophageal squamous cell carcinoma. Int J Cancer 2004;110:201-7.
11. Yamashita K, Mimori K, Inoue H, et al. A tumor suppressor role for trypsin in human cancer progression. Cancer Res 2003;63:6575-8.
12. Mimori K, Shiraishi T, Mashino K, et al. MAL gene expression in esophageal cancer suppresses motility, invasion, and tumorigenicity and enhances apoptosis through the Fas pathway. Oncogene 2003;22:3463-71.
13. Yamashita K, Park LM, Kim MS, et al. PGP9.5 methylation in diffuse type gastric cancer. Cancer Res 2006;66:3921-7.
14. Vogelstein B, Kinzler KW. Cancer genes and pathways they control. Nat Med 2004;10:789-99.
15. Lemaire F, Millon R, Muller D, et al. Loss of HOP tumor suppressor expression in head and neck squamous cell carcinoma. Br J Cancer 2004;91:258-61.
16. Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from lung tumor suppressor locus 3p21.3. Nat Genet 2000;25:315-9.
17. Yoshikawa H, Matsubara K, Qian GS, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth expression activity. Nat Genet 2001;28:29-35.
18. Kuramochi M, Fukuhara H, Nokubuni T, et al. TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet 2001;27:427-30.
19. Li Q-L, Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002;109:113-24.
20. Asanoma K, Matsuda T, kondo H, et al. NECC1, a candidate choriocarcinoma suppressor gene that encodes a homeobox consensus motif. Genomics 2003;81:15-25.
21. Shin CH, Liu ZP, Passier R, et al. Modulation of cardiac growth and development by HOP, an unusual homeodomain protein. Cell 2002;110:725-35.
22. Chen F, Kook H, Milewski R, et al. Hop is an unusual homeobox gene that modulates cardiac development. Cell 2002;110:713-23.
23. Poser S, Impey S, Trinh K, et al. SRF-dependent gene expression is required for PI3-kinase-regulated cell proliferation. EMBO J 2000;19:4955-66.
24. Kook H, Lepore JJ, Gitler AD, et al. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest 2003;112:863-71.
25. Yin Z, Gonzales L, Kolla V, et al. Hop functions downstream of Nkx2.1 and GATA6 to mediate HDAC-dependent negative regulation of pulumonary gene expression. Am J Physiol Lung Cell Mol Physiol 2006;291:L191-9.
26. Akiyama Y, Watkins N, Suzuki H, et al. GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol 2003;23:8429-39.
27. Nishida K, Mine S, Utunomiya T, et al. Global analysis of altered gene expressions during the process of esophageal squamous cell carcinogenesis in the rat: a study combined with a laser microdissection and a cDNA microarray. Cancer Res 2005;65:401-9.
28. Hoque MO, Feng Q, Toure P, et al. Detection of aberrant methylation of four genes in plasma DNA for detetion of breast cancer. J Clin Oncol 2006;24:4262-9.
29. Hoque MO, Begum S, Topalogu O, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 2006;98:996-1004.
30. Hoque MO, Topalogu O, Begum S, et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 2005;23:6569-75.
31. Xing M, Cohen Y, Mambo E, et al. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res 2004;64:1664-8.
32. Kang S, Lee JM, Jeon ES, et al. RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma. Int J Cancer 2006;119:1316-21.
33. Hibi K, Trink B, Patturajan M, et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A 2000;97:5462-7.
34. Brummelkamp T, Bernards R, Agami R: a system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550-3.